Skip to main content
. 2003 Dec;71(12):6899–6905. doi: 10.1128/IAI.71.12.6899-6905.2003

FIG. 1.

FIG. 1.

Prevalence of a positive ELISA for intestinal antilectin IgA antibodies in subjects cured of ALA (light bars) and controls (dark bars). The prevalence of antilectin IgA antibodies was greater in cases than controls at baseline (0 to 6 months) and during each follow-up period (P < 0.0001, for each). There was a significant decrease in the prevalence of antilectin IgA antibodies between baseline and follow-up intervals in ALA cases (P < 0.01 for each comparison) and in close associate controls (0 to 6 and 9 to 18 months compared to 21 to 36 months, P < 0.05).